SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Peterson BA,Petroni GR,Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003; 21: 515.
  • 2
    Hoppe R,Kushlan P,Kaplan H,Rosenberg SA,Brown BW. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood. 1981; 58: 592598.
  • 3
    Dana BW,Dahlberg S,Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993; 11: 644651.
  • 4
    Hagenbeek A,Eghbali H,Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol. 2006; 24: 15901596.
  • 5
    Solal-Celigny P,Brice P,Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996; 14: 514519.
  • 6
    Blum KA,Johnson JL,Niedzwiecki D, et al. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B study 9153. Cancer. 2006; 107: 28172825.
  • 7
    Robak T,Blonski JZ,Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000; 96: 27232729.
  • 8
    Robak T,Blonski J,Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006; 108: 473479.
  • 9
    Saven A,Emanuele S,Kosty M,Koziol J,Ellison D,Piro L. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995; 86: 17101716.
  • 10
    Cheson BD,Horning SJ,Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 12441253.
  • 11
    Young RC,Longo DL,Glatstein E,Ihde DC,Jaffe ES,DeVita VTJr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988; 25( suppl 2): 1116.
  • 12
    Brice P,Bastion Y,Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15: 11101117.
  • 13
    Ardeshna KM,Smith P,Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003; 362: 516522.
  • 14
    Klasa RJ,Meyer RM,Shustik C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol. 2002; 20: 46494654.
  • 15
    McLaughlin P,Hagemeister FB,Romaguera JE, et al. Fludarabine, mitoxantrone and dexamethasone: an effective regimen for indolent lymphoma. J Clin Oncol. 1996; 14: 12621268.
  • 16
    Lazzarino M,Orlandi E,Montillo M, et al. Fludarabine, cyclophosphamide and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol. 1999; 10: 5964.
  • 17
    Santini G,Nati S,Spriano M, et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica. 2001; 86: 282286.
  • 18
    Kalinka E,Wajs J,Sulek K, et al. Randomized multicenter trial of cladribine alone (C) or in combination with cyclophosphamide (CC), and COP in previously untreated low grade B-cell non-Hodgkin lymphoma patients: the first interim analysis [abstract]. Blood. 2004; 104: 3305a.
  • 19
    Pigaditou A,Rohatiner AZ,Whelan JS, et al. Fludarabine in low-grade lymphoma. Semin Oncol. 1993;(5 suppl 7): 2427.
  • 20
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 39093918.
  • 21
    Jurczak W,Rudzki Z,Galazka K, et al. High prevalence of non-Hodgkin's lymphomas in Polish population — 1106 new cases diagnosed according to WHO classification in only 1 district. Pol J Pathol. 2006; 57: 4552.
  • 22
    Hiddemann W,Kneba M,Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 37253732.
  • 23
    Marcus R,Imrie K,Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105: 14171423.
  • 24
    Herold M,Haas A,Srock S, et al. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma: four year follow-up results of a phase III trial of the East German Study Group Hematology and Oncology [abstract]. Blood. 2006; 108: 484a.
  • 25
    Foussard C,Mounier N,Van Hoof A, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients [abstract]. J Clin Oncol. 2006; 24: 7508a.
  • 26
    Forstpointner R,Dreyling M,Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 30643071.
  • 27
    Robak T,Smolewski P,Cebula B,Grzybowska-Izydorczyk O,Blonski JZ. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol. 2007; 79: 107113.
  • 28
    Robak T,Smolewski P,Cebula B,Szmigielska-Kaplon A,Chojnowski K,Blonski JZ. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer. 2006; 107: 15421550.
  • 29
    Ravandi F,O'Brien S. Infections associated with purine analogs and monoclonal antibodies. Blood Rev. 2005; 19: 253273.
  • 30
    Laszlo D,Galieni P,Raspadori D, et al. Fludarabine-containing regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma. 2000; 37: 157161.
  • 31
    Tournilhac O,Cazin B,Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004; 103: 363365.